McClain Mark S, Czajkowsky Daniel M, Torres Victor J, Szabo Gabor, Shao Zhifeng, Cover Timothy L
Department of Medicine, Vanderbilt University School of Medicine, and Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN 37232, USA.
Infect Immun. 2006 Nov;74(11):6188-95. doi: 10.1128/IAI.00915-06. Epub 2006 Sep 5.
VacA is a secreted toxin that plays a role in Helicobacter pylori colonization of the stomach and may contribute to the pathogenesis of peptic ulcer disease and gastric cancer. In this study, we analyzed a library of plasmids expressing randomly mutated forms of recombinant VacA and identified 10 mutant VacA proteins that lacked vacuolating cytotoxic activity when added to HeLa cells. The mutations included six single amino acid substitutions within an amino-terminal hydrophobic region and four substitutions outside the amino-terminal hydrophobic region. All 10 mutations mapped within the p33 domain of VacA. By introducing mutations into the H. pylori chromosomal vacA gene, we showed that secreted mutant toxins containing V21L, S25L, G121R, or S246L mutations bound to cells and were internalized but had defects in vacuolating activity. In planar lipid bilayer and membrane depolarization assays, VacA proteins containing V21L and S25L mutations were defective in formation of anion-selective membrane channels, whereas proteins containing G121R or S246L mutations retained channel-forming capacity. These are the first point mutations outside the amino-terminal hydrophobic region that are known to abrogate vacuolating toxin activity. In addition, these are the first examples of mutant VacA proteins that have defects in vacuolating activity despite exhibiting channel activities similar to those of wild-type VacA.
VacA是一种分泌性毒素,在幽门螺杆菌定殖于胃部过程中发挥作用,可能与消化性溃疡疾病和胃癌的发病机制有关。在本研究中,我们分析了一个表达重组VacA随机突变形式的质粒文库,并鉴定出10种突变VacA蛋白,当将其添加到HeLa细胞中时,这些蛋白缺乏空泡化细胞毒性活性。这些突变包括氨基末端疏水区域内的6个单氨基酸替换以及氨基末端疏水区域外的4个替换。所有10个突变均位于VacA的p33结构域内。通过将突变引入幽门螺杆菌染色体vacA基因,我们发现含有V21L、S25L、G121R或S246L突变的分泌型突变毒素可与细胞结合并被内化,但在空泡化活性方面存在缺陷。在平面脂质双层和膜去极化试验中,含有V21L和S25L突变的VacA蛋白在形成阴离子选择性膜通道方面存在缺陷,而含有G121R或S246L突变的蛋白保留了通道形成能力。这些是已知的氨基末端疏水区域外可消除空泡化毒素活性的首批点突变。此外,这些是首批尽管表现出与野生型VacA相似的通道活性但在空泡化活性方面存在缺陷的突变VacA蛋白实例。